Literature DB >> 10052865

Vascular nitric oxide may lessen Alzheimer's risk.

M F McCarty1.   

Abstract

Estrogen deficiency, hyperinsulinemia, type II diabetes, atherosclerosis, and a past history of elevated blood pressure may be associated with increased risk of Alzheimer's disease (AD). Common to all of these risk factors is a diminished capacity of vascular endothelium to generate nitric oxide (NO). Vascular NO has the potential to enhance the membrane polarization of cerebral neurons by increasing the open probability of calcium-activated potassium channels; this may protect neurons from the excessive calcium influx, potentiated by beta-amyloid peptides that is thought to mediate neuronal damage in AD. The possibility that NO/cyclic guanosine 3', 5'-phosphate (cGMP) may modulate the synthesis or processing of the amyloid precursor protein, also merits evaluation. Practical measures for promoting vascular NO production may include increased intakes of arginine, potassium, antioxidants, and fish-oil, as well as lifestyle measures that typically lower elevated blood pressure; potential benefits of chromium, glucosamine, and silicon should also be explored. In hypertensives, angiotensin-converting enzyme (ACE) inhibitors and sodium restriction may favorably influence endothelial function. Fish-oil should have the additional benefit of antagonizing the contribution of interleukin-1 to AD pathogenesis. Ancillary anti-excitotoxic measures such as magnesium, taurine, phenytoin, and vasodilators targeting ATP-dependent potassium (KATP) channels, may likewise reduce AD risk. Most of the nutritional measures suggested here would in any case be recommendable for preservation of vascular health.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052865     DOI: 10.1016/s0306-9877(98)90066-4

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  The neuroprotective effects of cocoa flavanol and its influence on cognitive performance.

Authors:  Astrid Nehlig
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 2.  Mechanisms of amyloid beta protein-induced modification in ion transport systems: implications for neurodegenerative diseases.

Authors:  J I Kourie
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

Review 3.  Synaptic therapy in Alzheimer's disease: a CREB-centric approach.

Authors:  Andrew F Teich; Russell E Nicholls; Daniela Puzzo; Jole Fiorito; Rosa Purgatorio; Mauro Fa'; Ottavio Arancio
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

4.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

5.  Flavanols, mild cognitive impairment, and Alzheimer's dementia.

Authors:  Ami K Patel; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Med       Date:  2008-04-15

6.  Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Jinsu Kim; Balasubramaniam Annamalai; Anandakumar Shunmugavel; Inderjit Singh; Avtar K Singh
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.

Authors:  Eugenia B Manukhina; H Fred Downey; Xiangrong Shi; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

Review 8.  Cyrcadian Rhythm, Mood, and Temporal Patterns of Eating Chocolate: A Scoping Review of Physiology, Findings, and Future Directions.

Authors:  Sergio Garbarino; Emanuela Garbarino; Paola Lanteri
Journal:  Nutrients       Date:  2022-07-28       Impact factor: 6.706

9.  Role of phosphodiesterase 5 in synaptic plasticity and memory.

Authors:  Daniela Puzzo; Salvatore Sapienza; Ottavio Arancio; Agostino Palmeri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.